Research Models and Biological Samples
Clinical Resources
Therapeutic and Diagnostic Development
Non-Hodgkin lymphoma
Research Models and Biological Samples
Therapeutic and Diagnostic Development
Diffuse large B-cell lymphoma (DLCBL)
Research Models and Biological Samples
Therapeutic and Diagnostic Development
clinical trial
NCT04920617 – DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
clinical trial
NCT04920617 – DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Chronic lymphocytic Leukemia (CLL)
Research Models and Biological Samples
Samples
Blasts derived from patients with CLL
In vivo models
Mice – CLL grafted mice (blasts)
Protocols
Tumor grafting in mice (CLL)
Therapeutic and Diagnostic Development
Samples
Blasts derived from patients with CLL
In vivo models
Mice – CLL grafted mice (blasts)
Protocols
Tumor grafting in mice (CLL)
Chronic myeloid leukemia (CML)
Research Models and Biological Samples
Samples
Blasts derived from patients with CML
In vivo models
Mice – CML grafted mice (blasts)
Protocols
Tumor grafting in mice (CML)
Therapeutic and Diagnostic Development
Samples
Blasts derived from patients with CML
In vivo models
Mice – CML grafted mice (blasts)
Protocols
Tumor grafting in mice (CML)
Acute lymphoblastic leukemia (ALL)
Research Models and Biological Samples
Samples
Blasts derived from ALL patients
In vitro models
Cell lines from patients with ALL
In vivo models
Mice – ALL grafted mice (blasts)
Therapeutic and Diagnostic Development
clinical trial
NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
Samples
Blasts derived from ALL patients
In vitro models
Cell lines from patients with ALL
In vivo models
Mice – ALL grafted mice (blasts)
clinical trial
NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
Systemic mastocytosis
Research Models and Biological Samples
Samples
Blood from patients with mastocytosis
Patient Cohorts
>500 Pediatric and adult (Mastocytosis)
Therapeutic and Diagnostic Development
Patents
Methods and pharmaceutical compositions for the treatment of mast cell diseases
Patents
Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
clinical trial
NCT04910685 – (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
clinical trial
NCT06186856 – Epidemiological Data on Mast Cell Pathologies in France
Samples
Blood from patients with mastocytosis
Patient Cohorts
>500 Pediatric and adult (Mastocytosis)
Patents
Methods and pharmaceutical compositions for the treatment of mast cell diseases
Patents
Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
clinical trial
NCT04910685 – (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
clinical trial
NCT06186856 – Epidemiological Data on Mast Cell Pathologies in France
Peripheral T-cell lymphoma
Research Models and Biological Samples
Therapeutic and Diagnostic Development
clinical trial
NCT04703192 – Valemetostat Tosylate (DS-3201b) an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
clinical trial
NCT04984837 – Study of Lacutamab in Peripheral T-cell Lymphoma
clinical trial
NCT05444712 – Transplantation After Complete Response In Patients With T-cell Lymphoma
clinical trial
NCT04703192 – Valemetostat Tosylate (DS-3201b) an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
clinical trial
NCT04984837 – Study of Lacutamab in Peripheral T-cell Lymphoma
clinical trial
NCT05444712 – Transplantation After Complete Response In Patients With T-cell Lymphoma
Myelodysplastic syndrome (MDS)
Research Models and Biological Samples
In vivo models
Mice – MDS grafted mice (bone marrow – blasts)
Protocols
Tumor grafting in mice (MDS)
Therapeutic and Diagnostic Development
Patents
Xpo1 antagonist kpt-251 for the treatment of myelodysplastic syndrome
clinical trial
NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
clinical trial
NCT05181735 – Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
In vivo models
Mice – MDS grafted mice (bone marrow – blasts)
Protocols
Tumor grafting in mice (MDS)
Patents
Xpo1 antagonist kpt-251 for the treatment of myelodysplastic syndrome
clinical trial
NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
clinical trial
NCT05181735 – Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Mantle cell lymphoma
Research Models and Biological Samples
Samples
Blasts derived from patients with mantle cell lymphoma
In vivo models
Mantle cell lymphoma grafted mice (blasts)
Protocols
Tumor grafting in mice (Mantle cell lymphoma)
Therapeutic and Diagnostic Development
clinical trial
NCT05471843 – Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
clinical trial
NCT04802590 – Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Samples
Blasts derived from patients with mantle cell lymphoma
In vivo models
Mantle cell lymphoma grafted mice (blasts)
Protocols
Tumor grafting in mice (Mantle cell lymphoma)
clinical trial
NCT05471843 – Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
clinical trial
NCT04802590 – Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Mast cell leukemia
Research Models and Biological Samples
Samples
Bone marrow from patients with mast cell leukemia
In vivo models
Mice – Mast cell leukemia grafted mice (bone marrow)
Protocols
Protocol with Mast cell leukemia grafted mice (bone marrow)
Protocols
Tumor grafting in mice (Mast cell leukemia)
Therapeutic and Diagnostic Development
Samples
Bone marrow from patients with mast cell leukemia
In vivo models
Mice – Mast cell leukemia grafted mice (bone marrow)
Protocols
Protocol with Mast cell leukemia grafted mice (bone marrow)
Protocols
Tumor grafting in mice (Mast cell leukemia)
HTLV-1-associated adult T-cell leukemia/lymphoma
Research Models and Biological Samples
Therapeutic and Diagnostic Development
Extranodal natural killer (NK)/T cell lymphoma (ENKTL)
Research Models and Biological Samples
Therapeutic and Diagnostic Development
EBV-induced B cell lymphoma
Research Models and Biological Samples
Therapeutic and Diagnostic Development
Classical Hodgkin lymphoma (cHL)
Research Models and Biological Samples
Therapeutic and Diagnostic Development
B-cell lymphoma
Research Models and Biological Samples
In vivo models
Mice – Human PDX in NOD SCID mice
Therapeutic and Diagnostic Development
In vivo models
Mice – Human PDX in NOD SCID mice
Anaplastic large cell lymphoma (ALCL)
Research Models and Biological Samples
Therapeutic and Diagnostic Development
Acute myeloid leukemia (AML)
Research Models and Biological Samples
Samples
Blasts derived from patients with AML
In vitro models
Cell lines from patients with AML
In vitro models
Human AML cell lines (AML)
In vivo models
Mice – AML grafted mice (blasts)
Protocols
Tumor grafting in mice (AML)
Patient Cohorts
Patient cohort associated with GOELAMS
Therapeutic and Diagnostic Development
clinical trial
NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
clinical trial
NCT05020665 – Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
clinical trial
NCT05193448 – A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
clinical trial
NCT05070208 – Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
clinical trial
NCT04777916 – Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
clinical trial
NCT05260528 – CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Samples
Blasts derived from patients with AML
In vitro models
Cell lines from patients with AML
In vitro models
Human AML cell lines (AML)
In vivo models
Mice – AML grafted mice (blasts)
Protocols
Tumor grafting in mice (AML)
Patient Cohorts
Patient cohort associated with GOELAMS
clinical trial
NCT03750994 – Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
clinical trial
NCT05020665 – Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
clinical trial
NCT05193448 – A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
clinical trial
NCT05070208 – Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
clinical trial
NCT04777916 – Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
clinical trial
NCT05260528 – CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
